PMID- 26426676
OWN - NLM
STAT- MEDLINE
DCOM- 20160915
LR  - 20151201
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Linking)
VI  - 47
IP  - 7
DP  - 2015
TI  - Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A 
      retrospective cohort analysis of the National Health Insurance database in 
      Taiwan.
PG  - 561-9
LID - 10.3109/07853890.2015.1091944 [doi]
AB  - PURPOSE: To evaluate the risk of acute pancreatitis hospitalization with 
      sitagliptin use in patients with type 2 diabetes mellitus (T2DM). METHODS: This 
      retrospective cohort analysis included newly diagnosed T2DM with onset age >/=25 
      years between 1999 and 2010 from the National Health Insurance database. Ever 
      users (n = 89,800) and never users (n = 449,000) of sitagliptin were followed 
      until end of 2011. A time-dependent approach was used to calculate event 
      incidence and estimate hazard ratios adjusted for propensity score. RESULTS: 
      During follow-up, 261 ever users and 5,840 never users were hospitalized for 
      acute pancreatitis (respective incidence, 224.0 and 168.4 per 100,000 
      person-years), with adjusted hazard ratio of 1.59 (95% CI 1.40-1.81). The 
      respective hazard ratio for the first, second, and third tertile of time since 
      starting sitagliptin <9.5, 9.5-21.0, and >21.0 months was 8.10 (6.80-9.65), 1.70 
      (1.38-2.11), and 0.41 (0.30-0.56); 3.26 (2.67-3.98), 1.86 (1.52-2.27), and 0.76 
      (0.59-0.98) for cumulative duration <3.7, 3.7-10.3, and >10.3 months; and 3.21 
      (2.65-3.90), 1.89 (1.54-2.32), and 0.73 (0.57-0.95) for cumulative dose <9,000, 
      9,000-28,000, and >28,000 mg. CONCLUSIONS: Sitagliptin is associated with a 
      higher risk of acute pancreatitis within the first 2 years of its initiation. The 
      risk diminishes thereafter, probably due to the depletion of susceptible 
      patients.
FAU - Tseng, Chin-Hsiao
AU  - Tseng CH
AD  - a Department of Internal Medicine , National Taiwan University College of 
      Medicine , Taipei , Taiwan.
AD  - b Division of Endocrinology and Metabolism, Department of Internal Medicine , 
      National Taiwan University Hospital , Taipei , Taiwan.
AD  - c Division of Environmental Health and Occupational Medicine of the National 
      Health Research Institutes , Zhunan , Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151001
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 0 (Hypoglycemic Agents)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Cohort Studies
MH  - Databases, Factual
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects/therapeutic use
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Pancreatitis/*epidemiology/etiology
MH  - Retrospective Studies
MH  - Risk
MH  - Sitagliptin Phosphate/*adverse effects/therapeutic use
MH  - Taiwan
MH  - Time Factors
OTO - NOTNLM
OT  - Acute pancreatitis
OT  - Taiwan
OT  - hospitalization
OT  - incretin
OT  - sitagliptin
EDAT- 2015/10/02 06:00
MHDA- 2016/09/16 06:00
CRDT- 2015/10/02 06:00
PHST- 2015/10/02 06:00 [entrez]
PHST- 2015/10/02 06:00 [pubmed]
PHST- 2016/09/16 06:00 [medline]
AID - 10.3109/07853890.2015.1091944 [doi]
PST - ppublish
SO  - Ann Med. 2015;47(7):561-9. doi: 10.3109/07853890.2015.1091944. Epub 2015 Oct 1.